Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel…
Company plans to initiate phase I/IIa in-human clinical trials in Q2 2023 Tel Aviv, Israel…
Pharmanovia to acquire license to GHRYVELIN™from Aeterna Zentaris’ existing licensee, Consilient Health, effective immediately TORONTO,…
–Interrogation of circulating tumor cells (CTCs) shows downregulation of KEAP1 gene promotes resistance to immune checkpoint…
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
The Company unveils brand name for its planned minoxidil hair regrowth product LOS ANGELES, March…
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) — SPR Therapeutics, a private medical device company focused…
INB-300, a gamma-delta T cell based chimeric antigen receptor (CAR) platform, demonstrated the ability to…
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) — PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company…
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated…
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are…
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET…
– Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway –…
Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE…
— NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business,…
NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early…
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoing Disclosure of…